Trial Profile
a Multicenter, Randomized, Open-label, Active-treatment, Controlled Trial to Compare the Efficacy of NOAC With Edoxaban vs. Dual Antiplatelet Therapy (DAPT) for Prevention of Leaflet Thrombosis (Documented by Cardiac CT Imaging) and Cerebral Embolization (Documented With Brain DW-MRI Imaging) in Patients Without an Absolute Indication for Chronic OAC After Successful TAVR
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2022
Price :
$35
*
At a glance
- Drugs Edoxaban (Primary) ; Aspirin; Clopidogrel
- Indications Intracranial embolism; Thrombosis
- Focus Therapeutic Use
- Acronyms ADAPT-TAVR
- 19 Sep 2022 Results(n=229) of Subgroup Analysis comparing incidence of leaflet thrombosis and cerebral thromboembolism in low-dose or standard-dose edoxaban with DAPT presented at the Transcatheter Cardiovascular Therapeutics 2022
- 04 Apr 2022 Primary endpoint (an incidence of leaflet thrombosis) has not been met as per the results published in the Circulation
- 04 Apr 2022 Results published in the Circulation